Teva wraps up Cephalon acquisition
Teva Pharmaceutical Industries Ltd. has closed its acquisition of Cephalon Inc. Teva said that as of Friday, Cephalon became a wholly owned subsidiary of and ceased to be traded on Nasdaq. The two pharmaceutical companies unveiled the $6.8 billion deal this past spring.